Skip to Main Content
Newsroom
BD & Partnering
Get in Touch
LinkedIn
X Mobile
Editas Medicine Linkedin
Research and Pipeline
CRISPR Gene Editing
For Patients
Who We Are
Join Our Team
Investors
Newsroom
BD & Partnering
Get in Touch
LinkedIn
X Mobile
Purchasing Policy Terms and Conditions
+
-
Editas Newsroom
Nov
9
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Oct
14
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Oct
8
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia